The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Identifying optimal treatment strategies for advanced HCC
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses the challenges of selecting the best treatment options for patients with advanced hepatocellular carcinoma (HCC), highlighting the lack of biomarkers or clinical characteristics to guide this decision. Treatment choices are currently based on clinical factors such as liver function, comorbidities, and concomitant medications. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Unfortunately, we don’t have biomarkers or clinical characteristics or clinical factors that can help us select the best treatment options for patients with advanced HCC. We have different immunotherapy combinations. We have tyrosine kinase inhibitors and all the translational parts of the trials did not identify specific biomarkers to select one treatment or the other...
Unfortunately, we don’t have biomarkers or clinical characteristics or clinical factors that can help us select the best treatment options for patients with advanced HCC. We have different immunotherapy combinations. We have tyrosine kinase inhibitors and all the translational parts of the trials did not identify specific biomarkers to select one treatment or the other. We now base our decision on clinical characteristics, for instance, the liver function, the comorbidities, concomitant medications, but actually it’s more of a clinical decision because we don’t have clear biomarkers or clinical factors that can really help us in our decision. So this is a huge unmet need and there are ongoing studies trying to identify some factors that can be helpful in selecting the treatment for patients with advanced HCC.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
